8月4日 - ** Vertex Pharmaceuticals VRTX.O股价在延时交易中下跌14%，报403.00美元。
** 该公司表示，在未能达到中期试验的主要目标后，将不再继续 (link)，而是将其实验性非阿片类止痛药作为一种单独疗法进行开发。
** VRTX 公布第二季度营收 29.6 亿美元，超过预期的 29.1 亿美元 - LSEG
** 公司维持年度预测，并补充说，预测包括关税带来的非实质性成本影响
** 截至上一交易日收盘，公司股价累计上涨 17
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.